anti-human CD19 T cell injection

Anti-human CD19 T cell injection (also known as HLX23) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Shanghai Henlius Biotech. The treatment involves the ex vivo genetic modification of a patient's own T cells to express a chimeric antigen receptor (CAR) that specifically targets the CD19 antigen, a protein highly expressed on the surface of most B-cell malignancies. Once re-infused into the patient, these engineered T cells recognize and bind to CD19-positive cells, triggering T-cell activation and the subsequent lysis of malignant B cells. This therapy has been investigated in Phase 1 clinical trials in China for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While Henlius initially developed this asset, the broader Fosun Pharma group (Henlius's parent) also manages the commercialization of axicabtagene ciloleucel in China through its joint venture, Fosun Kite.

Other names

抗人CD19 T细胞注射液anti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cells